Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma

Journal of Clinical Oncology

Volumn 28, Issue 33, 2010, Pages 4912-4918

  Hoskin, Peter J ^a   Rojas, Ana M ^a   Bentzen, Søren M ^a   Saunders, Michele I ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOGEN; NICOTINAMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CARCINOMA; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYSTOSCOPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION;

AGED; AGED, 80 AND OVER; CARBON DIOXIDE; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; OXYGEN; RADIATION-SENSITIZING AGENTS; URINARY BLADDER NEOPLASMS;

EID: 79951938429     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.4950     Document Type: Article

References (34)

1. Dunst J, Rodel C, Zietman A, et al: Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Semin Surg Oncol 20:24-32, 2001 (Pubitemid 32319330)
2. Efstathiou JA, Zietman AL, Kaufman DS, et al: Bladder-sparing approaches to invasive disease. World J Urol 24:517-529, 2006 (Pubitemid 44782306)
3. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866, 2003 (Pubitemid 37025405)
4. Gschwend JE, Fair WR, Vieweg J: Radical cystectomy for invasive bladder cancer: Contemporary results and remaining controversies. Eur Urol 38:121-130, 2000 (Pubitemid 30452312)
5. Paulson DF: Critical review of radical cystectomy and indicators of prognosis. Semin Urol 11: 205-213, 1993
6. Rodel C, Grabenbauer GG, Kuhn R, et al: Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 20:3061-3071, 2002 (Pubitemid 34791095)
7. Shipley WU, Kaufman DS, Zehr E, et al: Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer. Urology 60: 62-67, 2002 (Pubitemid 34722947)
8. Gospodarowicz M: Radiotherapy and organ preservation in bladder cancer: Are we ignoring the evidence? J Clin Oncol 20:3048-3050, 2002
9. Milosevic M, Gospodarowicz M, Zietman A, et al: Radiotherapy for bladder cancer. Urology 69: 80-92, 2007 (Pubitemid 46186481)
10. Gray LH, Conger AO, Ebert M, et al: The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638-648, 1953
11. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al: Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24:727-735, 2006 (Pubitemid 46622039)
12. Nordsmark M, Bentzen SM, Rudat V, et al: Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: An international multi-center study. Radiother Oncol 77:18-24, 2005 (Pubitemid 41503384)
13. Thomlinson RH, Gray LH: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9:539-549, 1955
14. Hoskin PJ, Sibtain A, Daley FM, et al: GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: Relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89:1290-1297, 2003 (Pubitemid 37363419)
15. Palit V, Phillips RM, Puri R, et al: Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncol Rep 14:909-913, 2005
16. Overgaard J: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6:509-518, 1994
17. Rojas A: ARCON: Accelerated radiotherapy with carbogen and nicotinamide. Br J Radiol 24:174-178, 1992
18. Hoskin PJ, Rojas AM, Phillips H, et al: Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. Cancer 103:2287-2297, 2005 (Pubitemid 40686573)
19. Kaanders JH, Pop LA, Marres HA, et al: ARCON: Experience in 215 patients with advanced head-andneck cancer. Int J Radiat Oncol Biol Phys 52:769-778, 2002 (Pubitemid 34158740)
20. Kaanders JH, Pop LA, Marres HA, et al: Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. Radiother Oncol 48:115-122, 1998 (Pubitemid 28423782)
21. Hoskin PJ, Rojas AM, Saunders MI, et al: Carbogen and nicotinamide in locally advanced bladder cancer: Early results of a phase-III randomized trial. Radiother Oncol 91:120-125, 2009
22. Pavy JJ, Denekamp J, Letschert J, et al: EORTC Late Effects Working Group: Late effects toxicity scoring: The SOMA scale. Radiother Oncol 35:11-15, 1995
23. Chahal R, Sundaram SK, Iddenden R, et al: A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol 43:246-257, 2003 (Pubitemid 36314236)
24. Horwich A, Dearnaley D, Huddart R, et al: A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol 75:34-43, 2005 (Pubitemid 40616792)
25. Pos FJ, van Tienhoven G, Hulshof MC, et al: Concomitant boost radiotherapy for muscle invasive bladder cancer. Radiother Oncol 68:75-80, 2003 (Pubitemid 37289339)
26. Kachnic LA, Kaufman DS, Heney NM, et al: Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 15:1022-1029, 1997 (Pubitemid 27106286)
27. Madersbacher S, Hochreiter W, Burkhard F, et al: Radical cystectomy for bladder cancer today: A homogeneous series without neoadjuvant therapy. J Clin Oncol 21:690-696, 2003 (Pubitemid 46621904)
28. Hautmann RE, Gschwend JE, de Petriconi RC, et al: Cystectomy for transitional cell carcinoma of the bladder: Results of a surgery only series in the neobladder era. J Urol 176:486-492, 2006 (Pubitemid 43927871)
29. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19:666-675, 2001 (Pubitemid 32120143)
30. Zietman AL, Shipley WU, Kaufman DS: Organ-conserving approaches to muscle-invasive bladder cancer: Future alternatives to radical cystectomy. Ann Med 32:34-42, 2000 (Pubitemid 30103430)
31. Hoskin P, Rojas A, Saunders M: Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: Mature results of a phase II nonrandomized study. Int J Radiat Oncol Biol Phys 73:1425-1431, 2009
32. Cowan RA, McBain CA, Ryder WD, et al: Radiotherapy for muscle-invasive carcinoma of the bladder: Results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 59:197-207, 2004 (Pubitemid 38501525)
33. Gospodarowicz MK, Rider WD, Keen CW, et al: Bladder cancer: Long-term follow-up results of patients treated with radical radiation. Clin Oncol (R Coll Radiol) 3:155-161, 1991
34. Kim HL, Steinberg GD: The current status of bladder preservation in the treatment of muscle invasive bladder cancer. J Urol 164:627-632, 2000 (Pubitemid 30637589)